XULI WANG

XULI WANG portrait
  • Research Assistant Professor, Radiology Som, University of Utah

Research

Research Summary

The research in Dr. Wang's laboratory focuses on the development of molecular imaging probes and nanotherapeutics to improve diagnosis and therapy for skeletal associated cancers, e.g. primary bone cancers, bone metastases, and multiple myeloma. The major research activities include: 1) Multimodality nanotherapeutics for bone metastatic cancers; 2) Novel MRI probes for early detection of osteolytic lesions; 3) Targeted theranostics for non-invasive imaging and therapy.

Research Statement

Dr. Wang has been assigned an independent and large laboratory space (approximately 1600 square feet) and private office in the Division of Radiobiology located in Research Park, the University of Utah. Currently the research activities in Wang laboratory include the development of novel biomaterials for imaging and therapy in hopes of improving diagnosis and treatment for diseases, particularly for advanced osteolytic cancers, including breast cancer, prostate cancer and multiple myeloma. The primary ongoing projects in Dr Wang's lab include: 1) Multimodality nanotherapeutics for cancer induced bone metastasis; 2) The development of biodegradable and biocompatible molecular imaging probes. These projects are currently sponsored by National Cancer Institute (NIH 1R01CA166941), the Department of Defense (DOD PC120872), and American Heart Association (11BGIA7430022), respectively.

Grants, Contracts & Research Gifts

  • An osteolytic stimuli-responsive nanotherapeutic system for bone metastases. PI: Xuli Wang. NIH/NCI, 05/10/2013 - 05/09/2018. Total project budget to date: $1,545,875.00
  • Targeted, On-demand Charge Conversional Nanotherapeutics for Advanced Prostate Cancer . PI: Xuli Wang. Department of Defense, 07/01/2013 - 06/30/2016. Total project budget to date: $335,250.00
  • Targeting NEK2 in Myeloma to Overcome Drug-resistance. PI: Fenghuang Zhan. Co-PI(s): Xuli Wang. Leukemia Lymphoma Society, 10/01/2011 - 09/30/2014. Total project budget to date: $600,000.00
  • Molecular Imaging Agents. PI: Xuli Wang. American Heart Association, 07/01/2011 - 06/30/2014. Total project budget to date: $140,000.00
  • Biocompatible, Biodegradable, and Enzymatic-Cleavable MRI Contrast Agents for Early Detection of Bone Metastatic Breast Cancer. PI: Xuli Wang. Department of Defense, 04/01/2011 - 03/31/2013. Total project budget to date: $112,000.00
  • Bone-Targeted Drug Delivery System. PI: Xuli Wang. Seed Grant, Utah BMT/Myeloma Program, University of Utah, 07/01/2010 - present. Total project budget to date: $20,000.00
  • Bone-Targeted Statin Delivery System. PI: Xuli Wang. Center for Clinical and Translational Science, University of Utah, 09/01/2010 - present. Total project budget to date: $37,500.00
  • Amphipathic oral chelators and radionuclide contamination. PI: Scott Miller. Co-PI(s): Xuli Wang. National Institute of Allergy and Infectious Diseases, 09/30/2006 - 09/29/2009. Total project budget to date: $1,905,800.00

Research Equipment and Testing Expertise

  • The following instruments are equipped in Dr. Wang’s Laboratory for Chemistry: HPLC (Agilent 1200), FT-IR (Varian 640), Chemical hoods (4X), UV-Vis spectrophotometer, Vacuum (4X), Rotary evaporator (Buchi), Ultrapure water purification system (Millipore), Vacuum concentrator, Freeze-dry system (Thermo Scientific).
  • The following instruments are available in Dr. Wang’s Laboratory for Bio-related studies: Cell culture hood, CO2 incubators, Microplate reader (Molecular Devices), GloMax multimode reader (Promega), Gel electrophoresis apparatus, UV transilluminator (UVP), Centrifuges, Scintillation counter (Beckman), -80°C ultrafreezer, Inverted light and fluorescence microscopes (Nikon).
  • Animal facilities: The Radiobiology Division has a dedicated animal facility which is located downstairs of Dr. Wang’s Laboratory. The animal facility includes 4 individual rodent rooms, cage cleaning room, and procedure suite.